Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats

Journal of Pharmacological Sciences

Volumn 127, Issue 3, 2015, Pages 260-274

  Liu, Yu Sheng ^a,b   Huang, Zhi Wei ^a   Wang, Lin ^a   Liu, Xin Xin ^a   Wang, Yong Mei ^b   Zhang, Yun ^a   Zhang, Mei ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Cardiac function; Diabetes mellitus; Myocardial remodeling; Sitagliptin

Indexed keywords

COLLAGEN; PROTEIN KINASE; RECEPTOR INTERACTING PROTEIN KINASE 3; SITAGLIPTIN; STREPTOZOCIN; UNCLASSIFIED DRUG; DIPEPTIDYL PEPTIDASE IV INHIBITOR; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RECEPTOR-INTERACTING PROTEIN 3, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD ANALYSIS; COLLAGEN METABOLISM; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DOWN REGULATION; DRUG EFFECT; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HEMODYNAMICS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIPID DIET; LIPID METABOLISM; LIPID STORAGE; LOW DRUG DOSE; MALE; MORPHOMETRICS; MYOCARDITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING; ANIMAL; CARDIAC MUSCLE; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIASTOLE; DISEASE MODEL; DRUG EFFECTS; ETIOLOGY; EXPERIMENTAL DIABETES MELLITUS; HEART LEFT VENTRICLE FUNCTION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; WISTAR RAT;

ANIMALS; APOPTOSIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIASTOLE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; LIPID METABOLISM; MALE; MYOCARDIUM; RATS, WISTAR; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; SITAGLIPTIN PHOSPHATE; STREPTOZOCIN; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84936876236     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1016/j.jphs.2014.12.007     Document Type: Article

References (35)

1. Cas AD, Spigoni V, Ridolfi V, Metra M. Diabetes and chronic heart failure: from diabetic cardiomyopathy to therapeutic approach. Endocr Metab Immune Disord Drug Targets. 2013;15(1):220-223.
2. Hamby RI, Zoneraich S, Sherman L. Diabetic cardiomyopathy. JAMA. 1974;229(13):1749-1754.
3. Sharifi AM, Mousavi SH, Farhadi M, Larijani B. Study of high glucose-induced apoptosis in PC12 cells: role of bax protein. J Pharmacol Sci. 2007;104(3):258-262.
4. Lee TI, Kao YH, Chen YC, Huang JH, Hsiao FC, Chen YJ. Peroxisome proliferatoractivated receptors modulate cardiac dysfunction in diabetic cardiomyopathy. Diabetes Res Clin Pract. 2013;8227(13):9-10.
5. Bai Y, Cui W, Xin Y, Miao X, Barati MT, Zhang C, et al. Preventionbysulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. J Mol Cell Cardiol. 2013; S0022-2828(13):00011-00014.
6. Sari FR, Watanabe K, Thandavarayan RA, Harima M, Zhang S, Muslin AJ, et al. 14-3-3 protein protects against cardiac endoplasmic reticulum stress (ERS) and ERS-initiated apoptosis in experimental diabetes. J Pharmacol Sci. 2010;113(4):325-334.
7. Zhang DW, Zheng M, Zhao J, Li YY, Huang Z, Li Z, Han J. Multiple death pathways in TNF-treated fibroblasts: RIP3- and RIP1-dependent and independent routes. Cell Res. 2011;21(2):368-371.
8. Vanlangenakker N, Vanden Berghe T, Bogaert P, Laukens B, Zobel K, Deshayes K, et al. Bertrand MJ.cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ. 2011;18(4):656-665.
9. Akarte AS, Srinivasan BP, Gandhi S. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats. Biochem Pharmacol. 2012;83(2):241-252.
10. Kim MK, Chae YN, Kim HD, Yang EK, Cho EJ, Choi SH, et al. DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. Life Sci. 2012;90(1-2):21-29.
11. Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K. Low, but physiological, concentration of GLP-1 stimulates insulin secretion independent of the cAMP-dependent protein kinase pathway. J Pharmacol Sci. 2008;108(3):274-279.
12. Yin M, Sillje HH, Meissner M, van Gilst WH, de Boer RA. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol. 2011;10(5):85-87.
13. Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One. 2012;7(12):111-113.
14. Yamazaki K, Inoue T, Yasuda N, Sato Y, Nagakura T, Takenaka O, et al. Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alphaglucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice. J Pharmacol Sci. 2007;104(1):29-38.
15. Ku HC, Chen WP, Su MJ. DPP-4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion. Naunyn Schmiedebergs Arch Pharmacol. 2011;384(2):197-207.
16. Ti Y, Xie GL, Wang ZH, Bi XL, Ding WY, Wang J, et al. TRB3 gene silencing alleviates diabetic cardiomyopathy in a type 2 diabetic rat model. Diabetes. 2011;60(11):2963-2974.
17. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
18. Sun M, Dawood F, Wen WH, Chen M, Dixon I, Kirshenbaum LA, et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation. 2004;110:3221-3228.
19. Bi XP, Tan HW, Xing SS, Wang ZH, Tang MX, Zhang Y, et al. Overexpression of TRB3 gene in adipose tissue of rats with high fructose-induced metabolic syndrome. Endocr J. 2008;55:747-752.
20. B1 Picatoste, Ramírez E, Caro-Vadillo A, Iborra C, Ares-Carrasco S, Egido J, et al. Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. PLoS One. 2013;21:e78330.
21. Yamasaki Y, Katakami N, Kaneto H, Nakajima K, Kusuoka H, Kashiwagi A, et al. Improved lipid profiles are associated with reduced incidence of coronary vascular events in asymptomatic patients with type 2 diabetes and impaired myocardial perfusion. J Atheroscler Thromb. 2012;18(11):1203-1206.
22. Akarte AS, Srinivasan BP, Gandhi S. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates/5-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes. J Diabetes Complications. 2012;26(4):266-274.
23. Satoh-Asahara N, Sasaki Y, Wada H, Tochiya M, Iguchi A, Nakagawachi R, et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism. 2012;10(11):135-137.
24. Noyan-Ashraf MH, Shikatani EA, Schuiki I, Mukovozov I, Wu J, Li RK, et al. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation. 2013;127(1):74-85.
25. Chaykovska L, von Websky K, Rahnenführer J, Alter M, Heiden S, Fuchs H, et al. Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS One. 2011;6(11):e27861.
26. Parlevliet ET, Wang Y, Geerling JJ, Schröder-Van der Elst JP, Picha K, O'Neil K, et al. GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE-/-mice. PLoS One. 2012;7(11):e49152.
27. Terasaki M, Nagashima M, Watanabe T, Nohtomi K, Mori Y, Miyazaki A, et al. Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice. Metabolism. 2012;61(7):974-977.
28. Giannocco G, Oliveira KC, Crajoinas RO, Venturini G, Salles TA, Fonseca-Alaniz MH, et al. Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats. Eur J Pharmacol. 2013;698(1-3):74-86.
29. Palaniyappan A, Uwiera RR, Idikio H, Menon V, Jugdutt C, Jugdutt BI. Attenuation of increased secretory leukocyte protease inhibitor, matricellular proteins and angiotensin II and left ventricular remodeling by candesartan and omapatrilat during healing after reperfused myocardial infarction. Mol Cell Biochem. 2013;30(1):223-225.
30. Zhu BM, Miyamoto S, Nagasawa Y, Wajima T, Hashimoto K. Effect of the sarcolemmal K (ATP) channel blocker HMR1098 on arrhythmias induced by programmed electrical stimulation in canine old myocardial infarction model: comparison with glibenclamide. J Pharmacol Sci. 2003;93(1):106-113.
31. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbøl EL, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32(15):19008.
32. Kwon DY, Kim YS, Ahn IS, Kim da S, Kang S, Hong SM, et al. Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats. J Pharmacol Sci. 2009;111(4):361-371.
33. Kim JY, Lim DM, Park HS, Moon CI, Choi KJ, Lee SK, et al. Exendin-4 protects against sulfonylurea-induced b-cell apoptosis. J Pharmacol Sci. 2012;118(1):65-74.
34. DeNicola M, Du J, Wang Z, Yano N, Zhang L, Wang Y, et al. Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium. Am J Physiol Endocrinol Metab. 2014;307(8):E630-E643.
35. Wu XM, Ou QY, Zhao W, Liu J, Zhang H. The GLP-1 analogue Liraglutide protects cardiomyocytes from high glucose-induced apoptosis by activating the Epac-1/Akt pathway. Exp Clin Endocrinol Diabetes. 2014;11(2):20-26.